Literature DB >> 1327769

Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.

A Vandermeers1, S Vandenborre, X Hou, P de Neef, P Robberecht, M C Vandermeers-Piret, J Christophe.   

Abstract

N-terminally shortened analogs of the 27-amino-acid and 38-amino-acid forms of the pituitary-adenylate-cyclase-activating neuropeptide, PACAP(1-27) and PACAP(1-38), were synthesized by a solid-phase method. Systematic deletion of the first 13 amino acids of both PACAP was tested by evaluating their ability to occupy the specific and selective PACAP receptor of human neuroblastoma NB-OK-1 cell membranes and to stimulate adenylate cyclase or, when inactive per se, to inhibit PACAP-stimulated adenylate cyclase activity. For each peptide, the Kact (concentration required for half-maximal adenylate cyclase activation) or Ki [concentration required to shift the dose/response curve of PACAP(1-27) twofold to the right] was in good agreement with the corresponding IC50 [concentration inhibiting 50% of 125I-[AcHis1]PACAP(1-27) binding to membranes], suggesting interaction with the same homogeneous class of adenylate cyclase-coupled receptors. The deletion of the two first amino acids (His1 and Ser2) sufficed to decrease the affinity for receptors and to suppress the capacity to activate adenylate cyclase. The shorter fragments 3-27 and 3-38, 4-27 and 4-38, 5-27 and 5-38, 6-27 and 6-38, 7-27 and 7-38, 8-27 and 8-38, and 9-27 and 9-38 were all competitive antagonists of PACAP(1-27)-stimulated activity with the N-terminally shortened PACAP(1-38) derivatives being 4-30-fold more potent than the equivalent PACAP(1-27) derivatives. In this group PACAP(6-38) was the most potent antagonist (Ki 1.5 nM). Surprisingly, the N-terminally shorter fragments 10-27 and 10-38, 11-27 and 11-38, 12-27 and 12-38, 13-27 and 13-38, and 14-27 and 14-38 were again able to stimulate adenylate cyclase, the smallest fragments, PACAP(14-27) and PACAP(14-38), being the most potent and efficient (Kact 2 microM and 0.1 microM, respectively). In this group of agonists, PACAP(1-38) derivatives deleted at the N-terminus were also more potent than the equivalent PACAP(1-27) derivatives.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327769     DOI: 10.1111/j.1432-1033.1992.tb17252.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

1.  Alternative splicing of the pituitary adenylate cyclase-activating polypetide (PACAP) receptor contributes to function of PACAP-27.

Authors:  Mina Ushiyama; Ryuji Ikeda; Morikatsu Yoshida; Kenji Mori; Kenji Kangawa; Hideki Sugawara; Kazuhiko Inoue; Katsushi Yamada; Atsuro Miyata
Journal:  J Mol Neurosci       Date:  2010-05-15       Impact factor: 3.444

2.  Biological and structural analysis of truncated analogs of PACAP27.

Authors:  Steve Bourgault; David Vaudry; Laure Guilhaudis; Emilie Raoult; Alain Couvineau; Marc Laburthe; Isabelle Ségalas-Milazzo; Hubert Vaudry; Alain Fournier
Journal:  J Mol Neurosci       Date:  2008-05-13       Impact factor: 3.444

3.  Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line.

Authors:  Tamás Juhász; Csaba Matta; Éva Katona; Csilla Somogyi; Roland Takács; Tibor Hajdú; Solveig Lind Helgadottir; János Fodor; László Csernoch; Gábor Tóth; Éva Bakó; Dóra Reglődi; Andrea Tamás; Róza Zákány
Journal:  J Mol Neurosci       Date:  2014-08-12       Impact factor: 3.444

4.  CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist.

Authors:  Yiming Lin; Randy A Hall; Michael J Kuhar
Journal:  Neuropeptides       Date:  2011-08-19       Impact factor: 3.286

5.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

6.  Developmental changes in pituitary adenylate cyclase activating polypeptide expression during the perinatal period: possible role in fetal gonadotroph regulation.

Authors:  Joseph P Moore; Betty C Villafuerte; Christian A Unick; Stephen J Winters
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

7.  Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells.

Authors:  D Reglodi; R Borzsei; T Bagoly; A Boronkai; B Racz; A Tamas; P Kiss; G Horvath; R Brubel; J Nemeth; G Toth; Z Helyes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

8.  Dopamine-2 receptor activation suppresses PACAP expression in gonadotrophs.

Authors:  Stephen J Winters; Dushan T Ghooray; Rong Q Yang; Joshua B Holmes; Andrew Rw O'Brien; Jay Morgan; Joseph P Moore
Journal:  Endocrinology       Date:  2014-05-13       Impact factor: 4.736

Review 9.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

10.  Agnathan VIP, PACAP and their receptors: ancestral origins of today's highly diversified forms.

Authors:  Stephanie Y L Ng; Billy K C Chow; Jun Kasamatsu; Masanori Kasahara; Leo T O Lee
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.